The Gabelli Global Mini Mites Fund on Tristel plc
Thesis
Tristel has a leadership position in medical disinfection products and is expanding internationally. FDA approvals make North America the company's largest growth opportunity, supported by a manufacturing and distribution partnership with Parker Laboratories. Gabelli believes easier-to-use products, strong gross margins, good free cash flow, and an asset-light model can support market-share gains and consistent earnings growth.
“we see Tristel as well positioned to take market share and grow earnings consistently in the mid to long term.”